Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation

Therapeutic Drug Monitoring

Volumn 21, Issue 2, 1999, Pages 161-165

  Dupuis, Robert E ^a   Sredzienski, Edward S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Cystic fibrosis; Lung transplantation; Pharmacokinetics; Tobramycin

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; PREDNISONE; THYMOCYTE ANTIBODY; TOBRAMYCIN;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; BAYES THEOREM; BODY SURFACE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; CYSTIC FIBROSIS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTI-BACTERIAL AGENTS; BAYES THEOREM; CYSTIC FIBROSIS; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MEDICAL RECORDS; POSTOPERATIVE CARE; PREMEDICATION; RETROSPECTIVE STUDIES; TOBRAMYCIN;

EID: 0032929088     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199904000-00004     Document Type: Article

References (23)

1. Egan TM, Detterbeck FC, Mill MR, Paradowski LJ, Lackner RP, et al. Improved results of lung transplantation for patients with cvstic fibrosis. J Thorac Cardiovasc Surg 1995;109:224-35.
2. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149:1601-7.
3. Kotloff RM, Zuckerman JB. Lung transplantation for cystic fibrosis. Special considerations. Chest 1996;109:787-98.
4. Bauer LA, Piecoro JJ, Wilson HD, Blouin RA. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin Pharm 1983;2:262-4.
5. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled trial. J Pediatr 1984;105:117-24.
6. Mann HJ, Canafax DM, Cipolle RJ, et al. Increased dosage requirements of tobramycin and gentamicin for treating pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985;1:238-243.
7. Horrevorts AM, Degener JE, Dzoljic-Danilovic G, et al. Pharmacokinetics of tobramycin in patients with cystic fibrosis: implications for the dosing interval. Chest 1985; 88:260-264.
8. Hendeles L, Iafrate RP, Stillwell PC, Mangos JA. Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to pharmacokinetic approach. J Pediatr 1987;110:303-10.
9. Bosso JA, Relling MV, Townsend PL, Strand LM. Intrapatient variation in aminoglycoside disposition in cystic fibrosis. Clin Pharm 1987;6:54-8.
10. Dupuis RE, Wire PD, Sredzienski ES. Tobramycin pharmacokinetics and dosing requirements in patients with cystic fibrosis preceding and following lung transplantation. Int Pharm Abst 1994; 29:2291.
11. deGroot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 1987;13:228-253.
12. Pleasants R, Williams D, Waltner W, Wager G, Knowles M. Comparative disposition of tobramycin in adult cystic fibrosis patients and normal adults [abstract]. Clin Pharmacol Ther 1989;45:150.
13. Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 1997;112:1208-13.
14. Howrie DL, Burckart GJ. Drug disposition in organ transplantation. In: Cook DR, Davis PJ, eds. Anesthetic Principles for Organ Transplantation. New York: Raven Ltd., 1994:55-81.
15. Fuhs DW, Mann HJ, Kubajak CAM, Cerra FB. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgical patients. Clin Pharm 1988;7:207-13.
16. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA: Applied Therapeutics Inc., 1992:14-1-14-47.
17. Kopp J, Klotman P. Cellular and molecular mechanisms of cyclosporine nephrotoxicity. J Am Soc Nephrol 1990;1:162-79.
18. Hansen JM, Fogh-Anderson N, Christensen NJ, Strandgaard S. Cyclosporine-induced hypertension and decline in renal function in healthy volunteers. J Hypertension 1997;15:319-26.
19. Perico N, Ruggenenti P, Gaspari F, et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992;54:56-60.
20. Deray G, Benhmida M, LeHoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Int Med 1992;117: 578-83.
21. Zaltzman JS, Pei Y, Maurer J, Patterson A, Cattran DC. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992;54:875-8.
22. Navis G, Broekroelofs J, Mannes GPM, et al. Renal hemodynamics after lung transplantation. A prospective study. Transplantation 1996;61:1600-5.
23. Zarowitz B, Robert S, Peterson EL. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother 1992;26:120-5-10.